Skip to main content
Erschienen in: Wiener klinisches Magazin 3/2013

01.06.2013 | Onkologie

Medikamentöse Therapie bei metastasierten neuroendokrinen Tumoren des gastroenteropankreatischen Systems

verfasst von: PD Dr. C.J. Auernhammer, C. Spitzweg, V. Heinemann, B. Göke

Erschienen in: Wiener klinisches Magazin | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Zusammenfassung

Neuroendokrine Neoplasien des gastroenteropankreatischen Systems werden nach der WHO-Klassifikation 2010 in neuroendokrine Tumoren (NET) und neuroendokrine Karzinome (NEC) unterteilt. Im klinischen Alltag spielt bei NET das Grading mithilfe des Ki-67-Proliferationsindex zur Prognoseabschätzung und Therapieplanung eine essenzielle Rolle. Zudem differieren die Tumorbiologie sowie die Therapieoptionen bei NET je nach Primariuslokalisation. Die palliative Therapie bei inoperablen NET umfasst lokal-ablative Maßnahmen bei ausschließlicher Lebermetastasierung, die peptidrezeptorvermittelte Radiotherapie (PRRT) bei Tumoren, die Somatostatinrezeptoren exprimieren, und verschiedene medikamentöse Therapieoptionen. In diesem Beitrag wird der aktuelle Stellenwert der Biotherapie mit Somatostatinanaloga und Interferon-α in der Symptom- und Tumorkontrolle beschrieben. Zudem werden die konventionelle Chemotherapie und neu zugelassene molekular zielgerichtete Therapieansätze mit Sunitinib und Everolimus bei NET des Pankreas dargestellt. Mögliche Therapiealgorithmen werden diskutiert.
Literatur
1.
Zurück zum Zitat Auernhammer CJ, Göke B (2011) Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin. Gut 60:1009–1021PubMedCrossRef Auernhammer CJ, Göke B (2011) Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin. Gut 60:1009–1021PubMedCrossRef
2.
Zurück zum Zitat Modlin IM, Pavel M, Kidd M, Gustafsson BI (2010) Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 31:169–188PubMed Modlin IM, Pavel M, Kidd M, Gustafsson BI (2010) Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 31:169–188PubMed
3.
Zurück zum Zitat Plöckinger U, Wiedenmann B (2007) Neuroendocrine tumors. Biotherapy. Best Pract Res Clin Endocrinol Metab 21:145–162PubMedCrossRef Plöckinger U, Wiedenmann B (2007) Neuroendocrine tumors. Biotherapy. Best Pract Res Clin Endocrinol Metab 21:145–162PubMedCrossRef
4.
Zurück zum Zitat Strosberg J, Kvols L (2010) Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol 16:2963–7290PubMedCrossRef Strosberg J, Kvols L (2010) Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol 16:2963–7290PubMedCrossRef
5.
Zurück zum Zitat Rinke A, Müller HH, Schade-Brittinger C et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27:4656–4663 Rinke A, Müller HH, Schade-Brittinger C et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27:4656–4663
6.
Zurück zum Zitat National Comprehensive Cancer Network (NCCN) (2011) Guidelines. http://www.nccn.org National Comprehensive Cancer Network (NCCN) (2011) Guidelines. http://​www.​nccn.​org
7.
Zurück zum Zitat North American Neuroendocrine Tumor Society (NANETS) (2010) Guidelines. http://nanets.net North American Neuroendocrine Tumor Society (NANETS) (2010) Guidelines. http://​nanets.​net
8.
Zurück zum Zitat Faiss S, Pape UF, Böhmig M et al (2003) Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors – the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21:2689–2696 Faiss S, Pape UF, Böhmig M et al (2003) Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors – the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21:2689–2696
9.
Zurück zum Zitat European Neuroendocrine Tumor Society (ENETS) (2009) Guidelines and standards of care. http://www.enets.org/ European Neuroendocrine Tumor Society (ENETS) (2009) Guidelines and standards of care. http://​www.​enets.​org/​
10.
Zurück zum Zitat Pavel ME, Baum U, Hahn EG et al (2006) Efficacy and tolerability of pegylated IFN-alpha in patients with neuroendocrine gastroenteropancreatic carcinomas. J Interferon Cytokine Res 26:8–13 Pavel ME, Baum U, Hahn EG et al (2006) Efficacy and tolerability of pegylated IFN-alpha in patients with neuroendocrine gastroenteropancreatic carcinomas. J Interferon Cytokine Res 26:8–13
11.
Zurück zum Zitat Fazio N, Braud F de, Delle Fave G, Oberg K (2007) Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination? Ann Oncol 18:13–19PubMedCrossRef Fazio N, Braud F de, Delle Fave G, Oberg K (2007) Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination? Ann Oncol 18:13–19PubMedCrossRef
12.
Zurück zum Zitat Moertel CG, Lefkopoulo M, Lipsitz S et al (1992) Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519–523 Moertel CG, Lefkopoulo M, Lipsitz S et al (1992) Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519–523
13.
Zurück zum Zitat Basch E, Prestrud AA, Hesketh PJ et al (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189–4198 Basch E, Prestrud AA, Hesketh PJ et al (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189–4198
14.
Zurück zum Zitat Ramanathan RK, Cnaan A, Hahn RG et al (2001) Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol 12:1139–1143PubMedCrossRef Ramanathan RK, Cnaan A, Hahn RG et al (2001) Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol 12:1139–1143PubMedCrossRef
15.
Zurück zum Zitat Strosberg JR, Fine RL, Choi J et al (2011) First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117:268–275PubMedCrossRef Strosberg JR, Fine RL, Choi J et al (2011) First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117:268–275PubMedCrossRef
16.
Zurück zum Zitat Bajetta E, Catena L, Procopio G et al (2007) Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 59:637–642PubMedCrossRef Bajetta E, Catena L, Procopio G et al (2007) Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 59:637–642PubMedCrossRef
17.
Zurück zum Zitat Maire F, Hammel P, Kianmanesh R et al (2009) Is adjuvant therapy with streptozotocin and 5-fluorouracil useful after resection of liver metastases from digestive endocrine tumors? Surgery 145:69–75PubMedCrossRef Maire F, Hammel P, Kianmanesh R et al (2009) Is adjuvant therapy with streptozotocin and 5-fluorouracil useful after resection of liver metastases from digestive endocrine tumors? Surgery 145:69–75PubMedCrossRef
18.
Zurück zum Zitat Moertel CG, Kvols LK, O’Connell MJ, Rubin J (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68:227–232PubMedCrossRef Moertel CG, Kvols LK, O’Connell MJ, Rubin J (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68:227–232PubMedCrossRef
19.
Zurück zum Zitat Mitry E, Baudin E, Ducreux M et al (1999) Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 81:1351–1355PubMedCrossRef Mitry E, Baudin E, Ducreux M et al (1999) Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 81:1351–1355PubMedCrossRef
20.
Zurück zum Zitat Hainsworth JD, Spigel DR, Litchy S, Greco FA (2006) Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol 24:3548–3554 Hainsworth JD, Spigel DR, Litchy S, Greco FA (2006) Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol 24:3548–3554
21.
Zurück zum Zitat Deutschbein T, Unger N, Yuece A et al (2011) Chemotherapy in patients with progressive, undifferentiated neuroendocrine tumors: a single-center experience. Horm Metab Res 43:838–843PubMedCrossRef Deutschbein T, Unger N, Yuece A et al (2011) Chemotherapy in patients with progressive, undifferentiated neuroendocrine tumors: a single-center experience. Horm Metab Res 43:838–843PubMedCrossRef
22.
Zurück zum Zitat Welin S, Sorbye H, Sebjornsen S et al (2011) Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer (im Druck) Welin S, Sorbye H, Sebjornsen S et al (2011) Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer (im Druck)
23.
Zurück zum Zitat Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514–523 Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514–523
24.
Zurück zum Zitat Yao JC, Pavel M, Phan AT et al (2011) Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab 96:3741–3749 Yao JC, Pavel M, Phan AT et al (2011) Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab 96:3741–3749
25.
Zurück zum Zitat Pavel ME, Hainsworth JD, Baudin E et al (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378:2005–2012PubMedCrossRef Pavel ME, Hainsworth JD, Baudin E et al (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378:2005–2012PubMedCrossRef
26.
Zurück zum Zitat Dong M, Yao JC (2011) mTOR inhibition, a potential novel approach for bronchial carcinoids. Endocr Relat Cancer 18:C15–C18PubMedCrossRef Dong M, Yao JC (2011) mTOR inhibition, a potential novel approach for bronchial carcinoids. Endocr Relat Cancer 18:C15–C18PubMedCrossRef
27.
Zurück zum Zitat Raymond E, Dahan L, Raoul JL et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501–513. Erratum in: N Engl J Med 364:1082 Raymond E, Dahan L, Raoul JL et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501–513. Erratum in: N Engl J Med 364:1082
28.
Zurück zum Zitat Jensen RT, Delle Fave G (2011) Promising advances in the treatment of malignant pancreatic endocrine tumors. N Engl J Med 364:564–565 Jensen RT, Delle Fave G (2011) Promising advances in the treatment of malignant pancreatic endocrine tumors. N Engl J Med 364:564–565
Metadaten
Titel
Medikamentöse Therapie bei metastasierten neuroendokrinen Tumoren des gastroenteropankreatischen Systems
verfasst von
PD Dr. C.J. Auernhammer
C. Spitzweg
V. Heinemann
B. Göke
Publikationsdatum
01.06.2013
Verlag
Springer Vienna
Erschienen in
Wiener klinisches Magazin / Ausgabe 3/2013
Print ISSN: 1869-1757
Elektronische ISSN: 1613-7817
DOI
https://doi.org/10.1007/s00740-013-0114-7

Weitere Artikel der Ausgabe 3/2013

Wiener klinisches Magazin 3/2013 Zur Ausgabe